ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1366	National Cancer Institute	Html	en	Pruritus (PDQ®)–Health Professional Version	Expert-reviewed information summary about pruritus (itching of the skin) as a complication of cancer or its treatment. Approaches to the management and treatment of pruritus are discussed.	pruritus 0.960641 second-generation antihistamines 0.585479 skin type 0.575303 atopic dermatitis 0.673145 skin surface 0.599366 worst pruritus 0.717892 atopic dermatitis population 0.574946 severe non-dermatological pruritus 0.718081 skin lipids 0.573883 Acad Dermatol Venereol 0.589376 primary dermatitis 0.600506 significant skin breakdown 0.59383 blood flow 0.584198 allergic skin reactions 0.594569 patients 0.575543 Dermatol Venereol Leprol 0.585578 placebo-controlled study 0.5912 radiation therapy 0.686843 Int J Dermatol 0.586614 Pain Symptom Manage 0.63754 healthy skin 0.593613 dry skin 0.639653 neuropathic pruritus 0.745005 et al. 0.592668	skin cleansing 0.573636 treatment 0.596222 skin reactions 0.599238 Oncol Nurs Forum 0.699339 skin dermatitis 0.603221 Opioid-induced Pruritus 0.704011 skin 0.704869 uraemic pruritus 0.705232 PUBMED Abstract 0.858232 Altered skin integrity 0.588103 Skin care 0.624412 Acta Derm Venereol 0.596823 pruritus relief 0.700635 itch 0.57584 allergic contact dermatitis 0.578553 skin hydration 0.574125 Clin Exp Dermatol 0.593566 skin change 0.583853 aggravates dry skin 0.598514 chronic idiopathic urticaria 0.638535 cholestatic pruritus 0.69774 Dermatol Ther 0.606265 intractable pruritus 0.703673 chronic pruritus 0.736276	CLICK HERE
1446	National Cancer Institute	Html	en	Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)–Patient Version	Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck.	cancer treatment 0.700679 oral mucositis pain 0.483396 tissue 0.465551 chemotherapy 0.631313 blood cell count 0.467595 mouth problems 0.466009 PDQ Oral Complications 0.468892 oral health exam 0.469677 mouth sores 0.537291 infections 0.470414 teeth 0.49264 neck radiation therapy 0.476468 high-dose chemotherapy 0.598756 cancer information summary 0.466904 oral mucositis 0.510415 stem cell transplant 0.72121 oral complications 0.763758 patients 0.61166 cancer patients 0.469036 radiation therapy patients 0.468456 dry mouth 0.687045 neck cancers 0.467921 radiation therapy 0.972855 Chronic dry mouth 0.472069 problems 0.532519	regular oral care 0.496586 oral care 0.520388 peroxide mouth rinses 0.475847 PDQ cancer information 0.50364 head 0.475462 mucous membranes 0.503677 mouth moist 0.469166 patient 0.472618 taste changes 0.470678 National Cancer Institute 0.465975 summary 0.488366 common oral complications 0.486948 Wipe mouth 0.467118 pain 0.536314 white blood cell 0.514465 tooth decay 0.48102 mouth guards 0.465834 gum disease 0.504216 salivary glands 0.547761 Managing Oral Complications 0.485092 PDQ summary 0.468583 mouth 0.82735 Different oral complications 0.468019 milder oral complications 0.467906	CLICK HERE
1462	National Cancer Institute	Html	en	Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors.	low-grade neuroendocrine tumors 0.396019 duodenal carcinoid tumor 0.397268 multifocal neuroendocrine tumors 0.421413 carcinoid patients 0.422833 relatively common carcinoids 0.388053 midgut neuroendocrine tumors 0.400819 midgut carcinoids 0.398106 carcinoid neuroendocrine tumors 0.530837 carcinoid heart failure. 0.412799 midgut carcinoid syndrome 0.494495 tract carcinoid tumors 0.466207 sporadic neuroendocrine tumors 0.41799 carcinoid heart disease 0.604399 multiple carcinoid tumors 0.498345 patients 0.441078 Pract Res Clin 0.384377 gastric carcinoids 0.406312 carcinoid symptoms 0.386144 Malignant carcinoid tumors 0.458841 ileal carcinoids 0.443228 carcinoid tumors 0.921678 Carcinoid Tumors section 0.552577 Gastrointestinal carcinoids 0.396139 term carcinoid 0.38666 gut neuroendocrine tumors 0.405828	gastric argyrophil carcinoid 0.39372 neuroendocrine tumors 0.772231 et al. 0.477186 carcinoid syndrome. 0.396106 renal carcinoid tumor 0.400621 rectal carcinoids 0.465534 Gastrointestinal Carcinoid Tumors 0.556816 rectal carcinoid patients 0.421651 carcinoids 0.607075 PUBMED Abstract 0.470567 multiple endocrine neoplasia 0.391617 frequent carcinoid tumor 0.405695 5-year survival 0.39049 neuroendocrine tumours 0.472335 neuroendocrine gastrointestinal tumors 0.422781 Pancreatic Neuroendocrine Tumors 0.446589 well-differentiated neuroendocrine tumors 0.443559 Abstract 0.585558 gastrointestinal carcinoid tumor 0.427766 carcinoid syndrome 0.595242 severe carcinoid heart 0.411522 gastroenteropancreatic neuroendocrine tumors 0.419971 metastatic carcinoid tumors 0.588139 duodenal carcinoids 0.494906	CLICK HERE
1628	National Cancer Institute	Html	en	Urethral Cancer Treatment (PDQ®)–Patient Version	Urethral cancer occurs in men and women and can spread quickly to lymph nodes near the urethra. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for urethral cancer.	cancer treatment 0.362333 entire urethra 0.306444 lymph node dissection 0.557244 tissue 0.317299 body 0.398643 PDQ cancer information 0.410389 clinical trial search 0.378188 white blood cells 0.310278 bladder cancer 0.308764 clinical trials 0.773033 nearby lymph nodes 0.630197 cancer information summary 0.370147 clinical trial 0.499273 breast cancer prevention 0.294123 prostate gland 0.293841 patients 0.324988 invasive bladder cancer 0.301679 treatment clinical trial 0.300741 NCI PDQ cancer 0.319347 radiation therapy 0.651339 Urethral Cancer Treatment 0.356944 Treatment Editorial Board 0.30592 urethral cancer 0.837946 recurrent urethral cancer 0.334114	General information 0.298754 treatment 0.543719 new cancer treatments 0.306575 NCI-supported cancer 0.322826 cancer cells 0.450964 proximal urethral cancer 0.41852 urethral cancer spreads 0.344537 Cancer Information Service 0.306473 laser surgery 0.302658 patient 0.295185 treatment clinical trials 0.339398 anterior exenteration 0.294741 National Cancer Institute 0.373731 transurethral resection 0.314195 new treatment 0.34401 distal urethral cancer 0.388721 external radiation therapy 0.308401 cancer research process 0.298298 cancer clinical trials 0.402611 cancer information summaries 0.303961 comprehensive cancer information 0.304414 internal radiation therapy 0.302856 cancer 0.977674 standard treatment 0.307427	CLICK HERE
1646	National Cancer Institute	Html	en	Cancer Screening Overview (PDQ®)–Patient Version	Information about measuring the effectiveness of cancer screening tests and about weighing the strength of the evidence obtained from cancer screening research studies.	new screening test 0.617185 health care provider 0.670679 odds ratio 0.601994 PDQ cancer information 0.657991 clinical trials 0.728892 cervical cancer rates 0.56941 test result 0.575182 cancer information summary 0.627344 group 0.594884 clinical trial 0.572791 test results 0.625142 breast cancer prevention 0.567805 cancer patients 0.585953 PDQ® Screening 0.567153 cancer risk factor 0.586088 cervical cancer 0.569926 relative risk 0.572167 symptoms 0.56993 cancer symptoms 0.5675 NCI PDQ cancer 0.589008 accurate cancer screening 0.616077 useful cancer screening 0.649307 PDQ Screening 0.5802 Cancer Information Service 0.580898	useful screening test 0.597804 Prevention Editorial Board 0.577411 certain disease 0.568589 National Cancer Institute 0.720252 studies 0.621784 certain gene mutations 0.593801 Screening trials 0.573937 Cancer Care page 0.570337 breast cancer 0.60178 people 0.685308 absolute risk 0.574938 standard screening test 0.598763 survival time 0.567302 screening test 0.737252 cancer screening tests 0.703056 cancer information summaries 0.578991 screening procedures 0.580721 comprehensive cancer information 0.579656 long cancer patients 0.576239 screening mammogram 0.574868 cancer 0.928642 information 0.71123 risk 0.62101 research studies 0.609116	CLICK HERE
1674	National Cancer Institute	Html	en	Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis.	Recurrent LCH 0.49021 cancer treatment 0.458844 childhood LCH lesions 0.545029 body 0.479436 high-risk multisystem LCH 0.563365 PDQ cancer information 0.430462 clinical trial search 0.417075 steroid therapy 0.417152 LCH lesions 0.646087 refractory childhood LCH 0.507141 Refractory LCH 0.491285 clinical trials 0.840496 LCH cells 0.723911 skin-only LCH 0.533026 cancer information summary 0.406099 clinical trial 0.546139 Langerhans cell histiocytosis 0.451003 patients 0.432765 LCH 0.976752 diagnose LCH 0.533565 lymph nodes 0.422079 treatment 0.665224 Progressive LCH 0.491974 BRAF gene 0.403636 LCH multisystem disease 0.521252	recurrent childhood LCH 0.508123 cancer cells 0.427036 pituitary gland 0.410888 childhood lch 0.600077 Adult LCH sections 0.511455 multisystem lch 0.599051 LCH trials 0.499932 LCH treatment 0.529717 treatment clinical trials 0.417639 National Cancer Institute 0.432317 effects cancer treatment 0.398781 small LCH lesions 0.540477 new treatment 0.409482 LCH bone lesions 0.547532 Adult LCH 0.522754 body systems 0.391142 LCH CNS 0.492291 bone marrow 0.4649 cancer clinical trials 0.44841 single-system lch 0.515862 progressive childhood LCH 0.507794 childhood LCH skin 0.522098 cancer 0.650545 information 0.432489	CLICK HERE
1984	National Cancer Institute	Html	es	Cuidados médicos de apoyo en niños (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer y como sobrevivientes adultos de cáncer.	among adult survivors 0.308012 Dev Behav Pediatr 0.311435 Last BF 0.307728 randomized controlled trials 0.307154 childhood cancer survivors 0.686811 Arch Gen Psychiatry 0.307642 largo plazo 0.386463 American Cancer Society 0.324849 Child Adolesc Psychiatry 0.308067 posttraumatic stress symptoms 0.324331 health-related quality 0.319663 Child Health Care 0.307161 adult survivors 0.332882 Hobbie WL 0.307769 suicidal ideation 0.309111 Pediatr Psychol 0.406392 stress symptoms during 0.307126 Health Care 0.307239 Grootenhuis MA 0.307795 Pediatr Nurs 0.308601 childhood cancer 0.948281 cancer survivor study 0.418789 células madre 0.316714 young adult survivors 0.314912 Phipps S 0.31239	adultos jóvenes 0.324674 Cancer Suppl 0.320779 Children’s Oncology Group 0.311705 leucemia linfoblástica aguda 0.307137 Cancer Facts 0.31467 posttraumatic stress 0.424392 Pediatr Blood Cancer 0.341708 sobrevivientes adultos 0.315742 efectos tardíos 0.308299 report from 0.327686 childhood leukemia 0.320175 during treatment 0.3081 Pediatr Oncol Nurs 0.312201 children with 0.442277 bone marrow transplant 0.30728 Pediatr Oncol 0.312328 Pediatr Hematol Oncol 0.312789 Clin Oncol 0.319255 sistema nervioso central 0.312739 tensión traumática 0.309229 Zebrack BJ 0.312471 surviving childhood 0.31989 Gartstein MA 0.308683 Zeltzer LK 0.312906	CLICK HERE
2042	National Cancer Institute	Html	es	Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga.	Cancer Inst Monogr 0.315885 Cancer Institute Surveillance 0.316979 urine cytology 0.306951 cuadro clínico 0.318123 Cancer Statistics Review 0.328453 transitional cell carcinoma 0.316775 Cancer registry problems 0.313029 Sin embargo 0.315264 American Cancer Society 0.340114 Hunt VB 0.306661 case-control study 0.305353 bladder cancer 0.978775 Young TB 0.311698 Bladder histological changes 0.316494 undergoing hematuria 0.308248 Malignant bladder tumors 0.31586 Can hematuria 0.308153 risk factors 0.306901 personas negras 0.307528 PDQ Exámenes 0.306867 patients with hematuria 0.310947 Messing EM 0.31983 Estados Unidos 0.311295 Natl Cancer Inst 0.403227 second cancers 0.320702	screening study using 0.305437 Bladder Cancer Group 0.328941 patients with 0.328907 neuropathic bladder 0.315447 SEER Cancer Statistics 0.328432 urinary tract 0.322774 Urol Clin North 0.310774 estadio t2+ 0.30573 detección casero 0.305242 Occup Med 0.308003 Cancer Facts 0.314556 bladder followed 0.315821 Noone AM 0.305423 National Cancer Institute 0.366947 Soloway MS 0.307825 Epidemiol Biomarkers Prev 0.327488 cell carcinoma 0.322375 asymptomatic microhematuria 0.311534 Clin North Am 0.316485 cell cytology screening 0.305294 bladder tumor 0.350128 invasive bladder 0.335021 bladder toxicity from 0.31599 transitional cell 0.318191	CLICK HERE
16381	National Cancer Institute	Html	es	Características genómicas de los cánceres infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las características genómicas de los cánceres infantiles. En este sumario se describen los subtipos moleculares de tipos específicos de cáncer infantil y las características clínicas relacionadas, las alteraciones genómicas recurrentes que caracterizan cada subtipo en el momento del diagnóstico o recidiva, y la importancia terapéutica y pronóstica de estas alteraciones. Se tratan las alteraciones genómicas relacionadas con tumores de encéfalo, tumores de riñón, leucemias, linfomas y otros tipos de cáncer.	frecuencia mutaciones 0.528888 genes mll 0.472072 Pediatric Acute Myeloid 0.497416 fusión npm-alk 0.439451 gen runx1t1 0.441044 North America 0.442782 IKZF1Las deleciones 0.453665 Sin embargo 0.617309 Katherine Tarlock 0.44723 mutaciones h3.3 0.551025 necesarias mutaciones 0.521725 secuencias codificadoras gfi1 0.437106 LLA hiperdiploide 0.80788 fusión il3-igh 0.467917 subtipo fab 0.455149 Ampliar Figura 0.451303 Pediatric Clinics 0.456212 Soheil Meshinchi 0.449095 gen etv6 0.449542 principales genes 0.447125 Otro gen 0.448963 GFI1 family oncogenes 0.435878 alteraciones genómicas tipo 0.497294 Genomic Variants 0.448917 gen mll 0.771285	células madre 0.513259 recaídas tardías 0.468538 leucemia linfoblástica aguda 0.548223 fusión bcr-abl1 0.481925 tipo ii 0.523537 gen runx1 0.541242 fusión etv6-runx1 0.484276 cromosoma filadelfia 0.948411 Acute Myeloid Leukemia 0.490135 valor pronóstico adverso 0.452162 Acute Lymphoblastic Leukemia 0.435296 células leucémicas hiperdiploides 0.488327 gen cbf-beta 0.443623 Age Group 0.442656 cromosomas hiperdiploidía 0.455258 Predisposition Genes 0.44826 fusión tcf3-hlf 0.515862 mutaciones activadoras 0.657624 Pediatric Oncology Group 0.437603 Therapeutic Implications 0.450243 genes jak 0.448326 Oncology Group 0.451583 subtipo fab m2 0.437855 determinados cánceres 0.434561	CLICK HERE
16835	National Cancer Institute	Html	en	Northwestern University — Cancer Nanotechnology Training Program	The focus of the Northwestern University Cancer Nanotechnology Training Center is presented here.	biological properties 0.685837 NU CCNE 0.813714 trainees 0.492664 Objectives 0.460665 cancer nanomaterials 0.715227 Ph.D 0.461621 tools 0.451616 basic courses 0.711616 research-based experiences 0.739642 skills 0.492332 career development programs 0.972187 MD 0.452108 PhD-level investigators 0.739449 centers 0.44872 National Cancer Institute 0.928332 Principal Investigator 0.787408 translational research 0.758394	clinical oncology 0.731649 International Institute 0.698015 needs 0.449442 Faculty 0.448884 Northwestern CNTC website 0.922154 Gayle Woloschak 0.790491 cancer patients 0.717775 eventual goal 0.748956 BioNanotechnology 0.51845 well-rounded curriculum 0.761183 efficacy 0.474176 nanotechnology resources 0.803175 principles 0.451682 Training Focus 0.735308 cancer biology 0.721666 training program 0.906256	CLICK HERE